Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use BRIXADI safely and effectively. See full prescribing information for BRIXADI. BRIXADI® (buprenorphine) extended-release injection for subcutaneous use CIII Initial U.S. Approval: 2002
Medication labelWhy this: Advisory · dailymed-prescription
BRIXADI is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.
- generic_name
- buprenorphine
- product_names
- BUPRENORPHINE
- ndc
- 58284-208, 58284-208-01, 58284-216, 58284-216-01, 58284-224, 58284-224-01, 58284-232, 58284-232-01, 58284-264, 58284-264-01, 58284-296, 58284-296-01, 58284-228, 58284-228-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en